↓ Skip to main content

PLOS

Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation

Overview of attention for article published in PLOS ONE, April 2012
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
82 Dimensions

Readers on

mendeley
86 Mendeley
Title
Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation
Published in
PLOS ONE, April 2012
DOI 10.1371/journal.pone.0035277
Pubmed ID
Authors

Yang Yu, Lan Zhang, Xiaojing Li, Xiaoqin Run, Zhihou Liang, Yi Li, Ying Liu, Moon H. Lee, Inge Grundke-Iqbal, Khalid Iqbal, David J. Vocadlo, Fei Liu, Cheng-Xin Gong

Abstract

Abnormal hyperphosphorylation of microtubule-associated protein tau plays a crucial role in neurodegeneration in Alzheimer's disease (AD). The aggregation of hyperphosphorylated tau into neurofibrillary tangles is also a hallmark brain lesion of AD. Tau phosphorylation is regulated by tau kinases, tau phosphatases, and O-GlcNAcylation, a posttranslational modification of proteins on the serine or threonine residues with β-N-acetylglucosamine (GlcNAc). O-GlcNAcylation is dynamically regulated by O-GlcNAc transferase, the enzyme catalyzing the transfer of GlcNAc to proteins, and N-acetylglucosaminidase (OGA), the enzyme catalyzing the removal of GlcNAc from proteins. Thiamet-G is a recently synthesized potent OGA inhibitor, and initial studies suggest it can influence O-GlcNAc levels in the brain, allowing OGA inhibition to be a potential route to altering disease progression in AD. In this study, we injected thiamet-G into the lateral ventricle of mice to increase O-GlcNAcylation of proteins and investigated the resulting effects on site-specific tau phosphorylation. We found that acute thiamet-G treatment led to a decrease in tau phosphorylation at Thr181, Thr212, Ser214, Ser262/Ser356, Ser404 and Ser409, and an increase in tau phosphorylation at Ser199, Ser202, Ser396 and Ser422 in the mouse brain. Investigation of the major tau kinases showed that acute delivery of a high dose of thiamet-G into the brain also led to a marked activation of glycogen synthase kinase-3β (GSK-3β), possibly as a consequence of down-regulation of its upstream regulating kinase, AKT. However, the elevation of tau phosphorylation at the sites above was not observed and GSK-3β was not activated in cultured adult hippocampal progenitor cells or in PC12 cells after thiamet-G treatment. These results suggest that acute high-dose thiamet-G injection can not only directly antagonize tau phosphorylation, but also stimulate GSK-3β activity, with the downstream consequence being site-specific, bi-directional regulation of tau phosphorylation in the mammalian brain.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 2 2%
Germany 1 1%
United Kingdom 1 1%
Spain 1 1%
United States 1 1%
Unknown 80 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 16 19%
Researcher 13 15%
Student > Master 13 15%
Student > Postgraduate 7 8%
Student > Bachelor 5 6%
Other 15 17%
Unknown 17 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 23 27%
Biochemistry, Genetics and Molecular Biology 15 17%
Chemistry 12 14%
Neuroscience 7 8%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 6 7%
Unknown 20 23%